MassBio And SCbio Select 10 Startups For Drive, Extending Early-Stage Support To Capital-Starved Founders
Jonathan Blake
Coverage
Healthcare Investment
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Latest
Truist Says Biotech Rebound Reached $136 Billion In Deals, As Financing And FDA Risks Ease
Daniel Cho
Biopharma Reverse Mergers Jump 1,600% In Q3, Giving Private Companies A Faster Route Public
Sophia Reynolds
Electra Files For Nasdaq IPO To Fund Ipsoprubart Phase 2/3 Program In sHLH
Daniel Cho
Most read
Sword Health Moves To Acquire Headspace, Extending Its Platform Into Mental Health
Daniel Cho
Generate Biomedicines Raises $400M in Major IPO for Advanced Severe Asthma Treatment
Daniel Cho
Vertex Pushes Biopharma M&A Momentum Into H2 2026 Amid IPO, VC Growth and FDA Uncertainty
Dr. Alex Morgan
Biotech IPOs Evolve: Caldera and Vidya Secure $478M via Reverse Go-Public Mergers
Dr. Priya Nandakumar
More in this beat
Aug 29, 2026AusperBio Raises $120 Million Series C To Push AHB-137 Through Phase 3 In Chronic Hepatitis B
The financing comes after AusperBio had already raised $37 million in series A in 2024 and a three-part series B across 2024-25 totaling $186 million. For investors, the signal is that capital is still available for hepatitis B programs that can pair late-stage momentum with a broader oligonucleotide platform story.
Sophia Reynolds
Aug 28, 2026Genentech Pays $45 Million Upfront For DualityBio ADCs, Targeting Post-Topoisomerase Resistance
Roche’s Genentech is licensing access to DualityBio’s Dupac payload platform as more patients receive first-line antibody-drug conjugates such as Enhertu and Trodelvy and then progress. DualityBio will take candidates into the clinic before Genentech assumes sole responsibility for development after phase 1a, combining Genentech’s portfolio reach with China-based early-stage development economics.
Dr. Alex Morgan
Aug 27, 2026JATT III Acquisition Raises $60 Million In Nasdaq IPO, Reopening A Biotech SPAC Playbook As Traditional Listings Recover
Someit Sidhu has brought a third biotech-focused SPAC to market just two months after pairing JATT II with Talawar Therapeutics. The new vehicle is targeting data-driven life sciences businesses, highlighting that even in a cooler SPAC market, sponsors still see openings around platform-heavy biotech stories.
Dr. Alex Morgan
Aug 26, 2026Biohaven Licenses Kv7 Epilepsy Platform To SK Biopharmaceutical For Up To $795 Million, Bolstering Cash Ahead Of Readouts
The agreement includes $400 million in near-term cash, up to $150 million in development and regulatory milestones, and the assumption of milestone obligations linked to Biohaven’s 2022 Knopp Biosciences agreement. For Biohaven, the deal strengthens the balance sheet as investors await data from the Phase 2/3 RISE3 trial in focal epilepsy.
Dr. Priya Nandakumar
Aug 26, 2026Haisco Forms Sentivera In Up To $1.5 Billion Immunology Deal, Extending Its U.S. Partnering Run
The agreement pairs a China-origin immunology asset with U.S. venture backing and a newco structure aimed at ex-China development. For Haisco, it adds another large outbound transaction in a year already marked by deals with Eli Lilly, Nuvectis and AbbVie.
Dr. Priya Nandakumar
Aug 26, 2026Biotech IPOs Reach 25 This Year, As Leerink Sees A More Selective Rebound
The current reopening looks different from the pandemic-era boom because investors are being more selective and still writing large checks when conviction is high. The main risks, according to Leerink’s Jack Bannister, are preclinical companies rushing out and issuers pushing valuation too far.
Dr. Priya NandakumarAug 26, 2026Sword Health Moves To Acquire Headspace, Extending Its Platform Into Mental Health
A filing with the Massachusetts Health Policy Commission says Headspace parent OrangeDot proposes to be acquired by Sword Health for cash, with an effective date of Sept. 14. The transaction value was not disclosed, but the move aligns with Sword’s push beyond virtual physical therapy and into mental health.
Daniel Cho
Aug 25, 2026TME Pharma Narrows NOX-A12 Partner Search To Two Parties, Keeping $1 Billion Peak-Sales Goal Alive
TME Pharma said it has entered the final evaluation phase of advanced discussions with two potential partners for NOX-A12, a CCL2 inhibitor also known as olaptesed pegol, in brain cancer. For a company that started the year with 2 million euros ($2.3 million) in the bank, the partnering process is not just strategic positioning but a prerequisite for the next clinical step.
Jonathan Blake
Aug 23, 2026Abcuro Raises $66 Million To Re-Run Ulviprubart In Less Severe IBM, After Prior Study Missed Statistical Significance
Abcuro is using fresh capital to narrow its development strategy around a subgroup that showed a stronger signal in an earlier study. The raise suggests investors still see a regulatory path for ulviprubart despite a setback in a trial that had been expected to support submission.
Emily Carter
Aug 22, 2026Capricor Investor Demands Board Change As Deramiocel Faces Aug. 22 FDA Decision
Capricor’s lead Duchenne muscular dystrophy cell therapy remains under FDA review after a 9-3 advisory committee vote against approval. At the same time, a significant shareholder is arguing that the company’s board has tied too much of Capricor’s capital and future to deramiocel while other programs sit paused.
Sophia Reynolds
Aug 22, 2026Ambros Strikes $150 Million Werewolf Merger Deal, Funding Neridronate Toward FDA Submission
The combined company will keep the Ambros name, remain based in San Diego and be led by current Ambros CEO Jay Hagan. Its lead asset, neridronate, is in an ongoing Phase 3 trial in complex regional pain syndrome type 1 and already holds breakthrough therapy, fast track and orphan drug designations from the FDA.
Jonathan Blake
Aug 20, 2026Scribe Therapeutics Rises 43% After $150 Million IPO, Defying Biotech’s Derisking Bias
Scribe raised an upsized $150 million and has climbed 43% from its first-day price of $21.50 to $31.05 by Wednesday’s close, compared with a 12% gain in the XBI over the last month. The company is heading into Phase 1 in Australia with STX-1150, a PCSK9-targeting epigenetic silencer that investors will begin to judge on interim patient data in the first half of next year.
Daniel ChoOther beats
AI in Drug Discovery
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Biopharmaceutical Industry
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Biotech Innovation
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Medical Technology
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Regulatory & Policy
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.